New drug cocktail aims to outsmart resistant uterine cancer
NCT ID NCT03675893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cancer type who have few other options. Researchers measure how long participants live without the cancer growing and whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letrozole, Abemaciclib, Metformin, Gedatolisib
What this could lead to
If successful, this could offer new combination treatment options for people with ER+ endometrial cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants. The drug combinations may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center (BIDMC)
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02214, United States
Contact Phone: •••-•••-••••
Contact